Socs2缺失改善JAK2-V617F驱动骨髓增殖性肿瘤小鼠模型对IFNα的分子学应答
研究在JAK2-V617F骨髓增殖性肿瘤(MPN)小鼠模型中探讨Socs2对聚乙二醇干扰素α(pegIFNα)应答的调控作用。删除Socs2可增强pegIFNα对JAK2突变造血干细胞的清除,并损害其二次移植功能;SOCS2抑制剂MN714联合IFNα在体外减少PV患者CD34+细胞输出优于单用IFNα。
要点
- JAK2-V617F小鼠中删除Socs2增加细胞因子敏感性,但未显著改变MPN表型。
- pegIFNα处理后,Socs2缺失增强JAK2突变造血干细胞清除,外周血和骨髓嵌合率较载体对照降低。
- Socs2缺失的JAK2突变造血干细胞在二次移植中功能受损,反映长期干性下降。
核心结论
- Socs2缺失增强pegIFNα清除JAK2突变造血干细胞克隆的效果。
- 靶向SOCS2可能改善接受干扰素治疗的MPN患者的治疗应答。
研究设计与样本
- 研究使用JAK2-V617F驱动的MPN小鼠模型,比较Socs2缺失与对照对pegIFNα的应答。
- 体外实验使用PV患者CD34+细胞,比较SOCS2抑制剂MN714联合IFNα与单用IFNα的效果。
主要发现
- JAK2-V617F小鼠删除Socs2后细胞因子敏感性增加,MPN表型无显著改变。
- pegIFNα处理后,Socs2缺失组外周血和骨髓嵌合率较载体对照组降低,JAK2突变造血干细胞清除增强。
- pegIFNα处理的Socs2缺失JAK2突变造血干细胞在二次移植中功能受损,干性长期下降。
- 体外实验中,MN714联合IFNα减少PV患者CD34+细胞输出的效果优于单用IFNα。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy with pegylated interferon alpha (pegIFNα) can induce a deep molecular response in a subset of patients with myeloproliferative neoplasms (MPN). Here we investigated the role of Socs2, a negative regulator of cytokine signaling, in modulating the response to pegIFNα in a JAK2-V617F mouse model of MPN. Deleting Socs2 in JAK2-V617F mice resulted in increased sensitivity to cytokines, without causing significant alterations in the MPN phenotype. When subjected to pegIFNα, the loss of Socs2 enhanced the depletion of JAK2-mutant hematopoietic stem cells (HSCs), evidenced by reduced chimerism in peripheral blood and bone marrow compared to vehicle controls. Additionally, pegIFNα-treated Socs2-deficient JAK2-mutant HSCs exhibited functional impairments in secondary transplantations, reflecting long-term detrimental decline of their stemness. These findings demonstrate that loss of Socs2 enhances the effectiveness of pegIFNα in depleting the JAK2-mutant HSC clone. In line with the genetic ablation of Socs2, the SOCS2 inhibitor MN714 combined with IFNα exhibited better efficacy than IFNα alone in reducing the output of CD34+ cells from PV patients in vitro. Targeting SOCS2 could therefore improve therapeutic responsiveness in MPN patients receiving interferon therapy.
引用
- Usart M, Kimmerlin Q, Stetka J, et al. Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025. PMID: 40069287. doi:10.1038/s41375-025-02550-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。